Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity

Pharmacogenetics and Genomics

Volumn 19, Issue 6, 2009, Pages 464-476

  Arefayene, Million ^a,b   Philips, Santosh ^a   Cao, Donghua ^a   Mamidipalli, Sudharani ^a   Desta, Zeruesenay ^a   Flockhart, David A ^a,b   Wilkes, David S ^a,c   Skaar, Todd C ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pharmacology and Toxicology ^*  (United States)

^c Microbiology and Immunology

Author keywords

2,3 dioxygenase; Functional genomics; Genetic variants; Immune tolerance; Indoleamine; Kynurenine; Tryptophan

Indexed keywords

COMPLEMENTARY DNA; ENZYME; INDOLEAMINE 2,3 DIOXYGENASE;

AFRICAN AMERICAN; ANIMAL CELL; ARTICLE; CATABOLISM; CELL STRAIN COS7; CELL STRAIN HEK293; CODING; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; EXON; GENE DELETION; GENE FREQUENCY; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOLOGICAL TOLERANCE; IN VITRO GENE TRANSFER; INDOLEAMINE 2,3 DIOXYGENASE1 GENE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL STRAIN COS1; CERCOPITHECUS; GENETIC TRANSFECTION; GENETICS; INTRON; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, COMPLEMENTARY; EXONS; GENETIC VARIATION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTRONS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; TRANSFECTION;

EID: 70149116670     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832c005a     Document Type: Article

References (43)

1. Grohmann U, Fallarino F, Bianchi R, Vacca C, Orabona C, Belladonna ML, et al. Tryptophan catabolism in nonobese diabetic mice. Adv Exp Med Biol 2003; 527:47-54.
2. Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, Lee J, et al. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol 2002; 57:143-150.
3. Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 2004; 30:311-318.
4. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004; 114:270-279.
5. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193.
6. Miki T, Sun H, Lee Y, Tandin A, Kovscek AM, Subbotin V, et al. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant Proc 2001; 33:129-130.
7. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51:356-365.
8. Swanson KA, Zheng Y, Heidler KM, Zhang ZD, Webb TJ, Wilkes DS. Flt3-ligand, IL-4, GM-CSF, and adherence-mediated isolation of murine lung dendritic cells: assessment of isolation technique on phenotype and function. J Immunol 2004; 173:4875-4881.
9. Malone DG, Dolan PW, Brown RR, Kalayoglu MV, Arend RA, Byrne GI, et al. Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. J Rheumatol 1994; 21:1011-1019.
10. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5:2516-2522.
11. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases and AIDS. Adv Exp Med Biol 1991; 294:425-435.
12. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10:1581-1591.
13. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-1274.
14. Konan KV, Taylor MW. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996; 271:19140-19145.
15. Tnani M, Bayard BA. Evidence for IRF-1-dependent gene expression deficiency in interferon unresponsive HepG2 cells. Biochim Biophys Acta 1999; 1451:59-72.
16. Travers MT, Gow IF, Barber MC, Thomson J, Shennan DB. Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta 2004; 1661:106-112.
17. Asnis GM, De La Garza R 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006; 40:322-335.
18. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19 (Suppl 3):S174-S178.
19. Burke F, Knowles RG, East N, Balkwill FR. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer 1995; 60:115-122.
20. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002; 71:1837-1848.
21. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95:1555-1561.
22. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 3:312-319.
23. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67:792-801.
24. Kadoya A, Tone S, Maeda H, Minatogawa Y, Kido R. Gene structure of human indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 1992; 189:530-536.
25. Waterman MS, Smith TF, Beyer WA. Some biological sequence metrics. Adv Math 1976; 20:367-387.
26. Chasman D, Adams RM. Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. J Mol Biol 2001; 307:683-706.
27. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 5:863-874.
28. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997; 43:2424-2426.
29. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999; 59:3171-3174.
30. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A 2006; 103:2611-2616.
31. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006; 34 (Web Server issue): W635-W641.
32. Habara-Ohkubo A, Takikawa O, Yoshida R. Cloning and expression of a cDNA encoding mouse indoleamine 2,3-dioxygenase. Gene 1991; 105:221-227.
33. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17-30. (Pubitemid 26029354)
34. Freimuth RR, Eckloff B, Wieben ED, Weinshilboum RM. Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. Pharmacogenetics 2001; 11:747-756.
35. Thomae BA, Eckloff BW, Freimuth RR, Wieben ED, Weinshilboum RM. Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J 2002; 2:48-56.
36. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 2001; 59:263-268.
37. Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J Exp Ther Oncol 2003; 3:336-345.
38. Kai S, Goto S, Tahara K, Sasaki A, Tone S, Kitano S. Indoleamine 2,3-dioxygenase is necessary for cytolytic activity of natural killer cells. Scand J Immunol 2004; 59:177-182.
39. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007; 396:203-213.
40. Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv Exp Med Biol 1996; 398:285-289.
41. Dang Y, Dale WE, Brown OR. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med 2000; 28:615-624.
42. Lin YC, Chen CL, Nakano T, Goto S, Kao YH, Hsu LW, et al. Immunological role of indoleamine 2,3-dioxygenase in rat liver allograft rejection and tolerance. J Gastroenterol Hepatol 2007; 23 (7 Pt 2):e243-e250.
43. Batabyal D, Yeh SR. Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase. J Am Chem Soc 2007; 129:15690-15701.